The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new ...

A new study reveals that semaglutide, a common diabetes medication, may effectively treat fatty liver disease, offering hope ...

A decision is expected in the fourth quarter of 2025.

Semaglutide is the key component of weight loss and diabetes drugs like Ozempic and Wegovy, and an international team of ...

An international study led by the director of Virginia Commonwealth University’s liver institute suggests that the substance ...

Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...

Semaglutide - the active ingredient in medications like Ozempic and WeGovy - is only FDA approved for Type-2 diabetes, but ...

CVS Caremark has selected Novo Nordisk’s Wegovy as the preferred GLP-1 medication for its largest commercial template formularies, effective July 1. In March, Novo Nordisk launched NovoCare Pharmacy ...

Research revealed that medications widely used for diabetes and obesity may offer significant benefits for patients with ...

A study has found that Ozempic may reverse signs of a disease that contributes to 2,000,000 deaths per year. New research has ...

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) submission for an investigational once-daily, 25 mg oral formulation of Wegovy® ...